Results 161 to 170 of about 16,492 (195)

Potential of Proprotein Convertase Subtilisin/Kexin Type 9 Based Therapeutics

Current Atherosclerosis Reports, 2013
The link between proprotein convertase subtilisin/kexin type 9 (PCSK9) and cholesterol metabolism was established only in 2003 when genetic mapping and positional cloning in patients with autosomal dominant hypercholesterolemia in which linkage to the loci coding for the LDL receptor and apolipoprotein B had been excluded identified the genetic defect ...
Evan A, Stein, Gary D, Swergold
openaire   +2 more sources

A Novel Splicing Variant of Proprotein Convertase Subtilisin/Kexin Type 9

DNA and Cell Biology, 2008
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is the most recently identified member of the proprotein convertase family. Genetic and cell biology studies have suggested a critical role of PCSK9 in regulating low-density lipoprotein receptor (LDLR) protein levels and thus modulating plasma LDL cholesterol. Recent data on the molecular basis for
Robert J, Schmidt, Youyan, Zhang, Yang, Zhao, Yue-Wei, Qian, He, Wang, Aimin, Lin, Maria E, Ehsani, Xiaohong, Yu, Guoming, Wang, Jaipal, Singh, Eric W, Su, Shuyu, Li, Robert J, Konrad, Guoqing, Cao   +13 more
openaire   +2 more sources

Proprotein Convertase Subtilisin/kexin type 9 Inhibition in Cardiovascular Prevention

Current Pharmaceutical Design, 2018
Elevated levels of Low Density Lipoprotein cholesterol (LDL-C) are directly associated with increased risk for atherosclerotic cardiovascular and cerebrovascular events. Statins have been used to control serum LDLC and this has translated into reduction in cardiovascular and cerebrovascular events.
Ali, Ali, Pierluigi, Costanzo, Angela, Hoye   +2 more
openaire   +2 more sources

The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasis

Journal of Internal Medicine, 2009
Abstract.The LDL receptor (LDLR) plays an essential role in the regulation of plasma (LDL) cholesterol concentrations by virtue of its ability to clear plasma LDL. Down‐regulation of the LDLR by proprotein convertase subtilisin/kexin 9 (PCSK9) has recently emerged as a regulatory mechanism that controls plasma LDL cholesterol concentrations. Studies in
S A, Mousavi, K E, Berge, T P, Leren
openaire   +2 more sources

The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Hyperlipidemia

American Journal Cardiovascular Drugs, 2011
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of circulating levels of low-density lipoprotein (LDL) particles. PCSK9 acts mainly by enhancing degradation of the LDL receptor in the liver. Several gain-of-function and loss-of-function mutations in the PCSK9 gene have been identified and linked to hypercholesterolemia and ...
openaire   +2 more sources

Mouse Models of Human Proprotein Convertase Insufficiency

Endocrine Reviews, 2021
Iris Lindberg, Lindberg Iris
exaly  

Proprotein convertase subtilisin/kexin type 9 in human disease

2011
Cardiovascular disease (CVD) is the leading cause of death in the 21st century. Among risk factors, hypercholesterolemia and abdominal obesity are directly linked to premature development of atherosclerosis. Familial hypercholesterolemia, commonly due to low-density lipoprotein receptor (LDLR) deficiency, is known to cause premature atherosclerosis and
openaire   +1 more source

Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis

Stroke, 2020
Jeffrey Saver, Marc Sabatine, Anthony Keech   +2 more
exaly  

Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Beyond Lipids: The Role in Oxidative Stress and Thrombosis

Antioxidants, 2022
Pasquale Pignatelli, Isabella Russo, Francesca Santilli   +2 more
exaly  

Proprotein convertase subtilisin/kexin 9 (PCSK9)

Science-Business eXchange, 2008
openaire   +1 more source